Prurigo nodularis (PN) presents with excoriated nodules on the extensor surfaces of limbs and trunk. It is commonly seen in persons infected with human immunodeficiency virus (HIV) and with low CD4 counts. 1 The pathogenesis of PN is not well understood, but it may be related to inflammatory mediators. [2] [3] [4] Interestingly, combination therapy that includes raltegravir, an integrase inhibitor that prevents viral DNA insertion into host cell DNA, has been noted to rapidly reduce viral load to levels comparable to or lower than other HIV antiretroviral therapies (ARTs). 5, 6 We report 2 cases of PN that dramatically improved within 2 weeks of initiating twice daily oral dosing with raltegravir, 400 mg.
tenofovir (Truvada; Gilead, Foster City, California), he experienced lesion recession and a dramatic decrease in pruritus, an improvement maintained at 6-month follow-up. In the preceding 5 years, his ART remained unchanged, aside from switching nevirapine to efavirenz 2 years prior. Previous 5-year CD4 cell counts and viral loads ranged from 4 to 190/μL (median, 79/μL) and from less than 75 to 177 952 copies/mL. Notably, CD4 cell counts from the previous 2 years ranged from 76 to 218/μL with a maximum viral load of 13 374 copies/mL and a viral load of lower than 75 copies/mL in the 8 months after commencement of combination raltegravir therapy.
Comment
The response of both of our patients to HIV ART that includes raltegravir is notable given the persistent prior disease course and the rapidity of the therapeutic response. The 2-week response time indicates that effects due to reduction of viremia may play a significant role in initial recession of PN rather than immune recovery associated with increased CD4 cell counts. Antiretroviral therapy that includes raltegravir has been documented to reduce viremia to levels lower than those achieved by other ART combinations. 5, 6 It is also conceivable that raltegravir may have a direct effect on the cytokine milieu regardless of its potent antiviral properties. In addition to suggesting inflammation as a mediator of PN, this response to raltegravir offers practitioners another consideration when tailoring ART. While there exists a report of occasional raltegravir-associated pruritus in a phase 2 trial, 7 this association was not reproduced in more recent and larger investigations, 8 and there are no reports of prurigo nodularis associated with raltegravir therapy. Arch Dermatol. Author manuscript; available in PMC 2015 November 06.
